Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Key Points

• Eric Lefkofsky sold 166,250 shares on March 26 at an average price of $46.38 for $7.71M, reducing his stake by 1.84% to 8,875,033 shares valued at about $411.6M.
• Tempus shares trade below their 50‑day ($55.11) and 200‑day ($69.73) moving averages and have a high beta (5.29), signaling elevated volatility; the company has a market cap of ~$7.62B and a negative trailing P/E (~-30.2).
• Analysts and institutions remain engaged: MarketBeat shows a consensus "Moderate Buy" with a $78.62 target, while investors like RBC, Swiss National Bank and ARK have increased or initiated positions and Tempus announced a collaboration with Daiichi Sankyo.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the firm's stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $46.38, for a total transaction of $7,710,675.00. Following the transaction, the chief executive officer directly owned 8,875,033 shares in the company, valued at $411,624,030.54. The trade was a 1.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $42.62 on Friday. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The stock has a market capitalization of $7.62 billion, a price-to-earnings ratio of -30.23 and a beta of 5.29. The company has a 50-day simple moving average of $55.11 and a 200-day simple moving average of $69.73. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Tempus AI by 201.2% during the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company's stock worth $1,253,000 after purchasing an additional 17,359 shares during the period. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the 1st quarter valued at approximately $116,000. Cetera Investment Advisers lifted its holdings in shares of Tempus AI by 18.8% in the 2nd quarter. Cetera Investment Advisers now owns 32,417 shares of the company's stock valued at $2,060,000 after buying an additional 5,123 shares during the period. Swiss National Bank purchased a new stake in shares of Tempus AI in the second quarter valued at approximately $9,175,000. Finally, Legal & General Group Plc boosted its stake in shares of Tempus AI by 24.4% in the second quarter. Legal & General Group Plc now owns 450,645 shares of the company's stock valued at $28,634,000 after buying an additional 88,373 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on TEM shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tempus AI in a research report on Thursday, January 22nd. Canaccord Genuity Group dropped their target price on Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, December 22nd. Stifel Nicolaus set a $60.00 price target on Tempus AI in a research note on Wednesday, February 25th. Wall Street Zen downgraded Tempus AI from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $78.62.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus "Moderate Buy" rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. NASDAQ: TEM Receives Consensus Rating of "Moderate Buy" from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.